Loading...
  • molecule
  • 2. The antibody molecule of claim 1, wherein amino acid residues 71, 73 and 78 in said composite heavy chain are additionally donor residues. (google.ca)
  • 3. The antibody molecule of claim 1, wherein amino acid residues 26 to 30 and 59 to 65 in said composite heavy chain are additionally donor residues. (google.ca)
  • 4. The antibody molecule of claim 1, wherein at least one of amino acid residues 1, 3, and 76 in said composite heavy chain are additionally donor residues. (google.ca)
  • 9. The antibody molecule of claim 8, wherein amino acid residues 1, 3 and 47 in said composite light chain are additionally donor residues. (google.ca)
  • Overexpression of the measles virus (MV) receptor CD46 in many tumour cells may direct the virus to preferentially enter transformed cells and there is increasing awareness of the importance of nectin-4 and signaling lymphocytic activation molecule (SLAM) in oncolysis. (mdpi.com)
  • Dörig RE, Marcil A, Chopra A, Richardson CD (1993) The human CD46 molecule is a receptor for measles virus (Edmonston strain). (springer.com)
  • conjugate
  • SAN DIEGO--( BUSINESS WIRE )--Fortis Therapeutics, Inc., an immuno-oncology biotech developing a novel antibody-drug conjugate (ADC) against CD46, today announced the U.S. Food and Drug Administration (FDA) has cleared two investigational new drug (IND) applications for the company's lead candidate, FOR46, for the treatment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma. (businesswire.com)
  • Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer. (businesswire.com)
  • This heptavalent-KLH conjugate plus QS21 vaccine safely induced antibody responses against five of seven antigens. (aacrjournals.org)
  • IgG1
  • Antibody Class: IgG1. (qedbio.com)
  • IgG1 showed higher bactericidal activity than IgG3 when directed against PorA (an abundant antigen), while IgG3 was more bactericidal than IgG1 when directed against FHbp (a sparsely and variably distributed antigen). (asm.org)
  • On the other hand, the IgG3 hinge-truncated antibodies IgG3m15 and IgGm17 showed higher bactericidal activity than both IgG1 and IgG3 regardless of the target antigen. (asm.org)
  • Thus, the Fc region of IgG3 antibodies appears to have an enhanced complement-activating function, independent of their long hinge region, compared to IgG1 antibodies. (asm.org)
  • By using monoclonal hapten (4-hydroxy-3-nitrophenacetyl [NP/NIP])-specific antibodies of all four IgG isotypes, we have demonstrated that IgG1 and IgG3 are best in inducing complement-mediated cellular lysis and IgG1 performs better than IgG3 when the antigen concentration on the target cells is high, while IgG3 performs better than IgG1 when the antigen concentration on the target cells is low ( 20 , 21 ). (asm.org)
  • In separate studies, IgG3 antibodies also showed higher SBA than IgG1 antibodies when the target antigen was sparsely expressed (as in the case of FHbp) ( 22 ), but IgG1 antibodies were more bactericidal than IgG3 antibodies when the target antigen was highly expressed, such as for PorA ( 23 ). (asm.org)
  • carcinoembryonic antigen
  • Successful attempts to retarget MV by inserting genes for tumour-specific ligands to antigens such as carcinoembryonic antigen (CEA), CD20, CD38, and by engineering the virus to express synthetic microRNA targeting sequences, and "blinding" the virus to the natural viral receptors are exciting measures to increase viral specificity and enhance the oncolytic effect. (mdpi.com)
  • membrane
  • membrane cofactor protein) is a multifunctional cell surface transmembrane protein that binds and inactivates C3b and C4b complement fragments, regulates T cell-induced inflammatory responses by either inhibiting (CD46-1 isoform) or increasing (CD46-2 isoform) the contact hypersensitivity reaction. (sysmex-flowcytometry.com)
  • CD46 is a protector of placental tissue and is also expressed on the inner acrosomal membrane of spermatozoa. (sysmex-flowcytometry.com)
  • Okada N, Liszewski MK, Atkinson JP, Caparon M: Membrane cofactor protein (CD46 is a keratinocyte receptor for the M protein of the group A streptococcus. (sysmex-flowcytometry.com)
  • Fleischli C, Verhaagh S, Havenga M, Sirena D, Schaffner W, Cattaneo R, Greber UF, Hemmi S: The distal short consensus repeats 1 and 2 of the membrane cofactor protein CD46 and their distance from the cell membrane determine productive entry of species B adenovirus serotype 35. (sysmex-flowcytometry.com)
  • Fleischli C, Sirena D, Lesage G, Havenga MJ, Cattaneo R, Greber UF, Hemmi S: Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor. (sysmex-flowcytometry.com)
  • PorA can induce bactericidal antibodies in humans and mice when they are immunized with meningococcal outer membrane vesicle (OMV) vaccines ( 4 - 8 ), and monoclonal antibodies (MAbs) against PorA can be protective in an infant rat model ( 9 ). (asm.org)
  • serum
  • There has recently been a considerable amount of interest regarding the possible association of HHV6 with multiple sclerosis (MS), based on the detection of HHV6 DNA in the brain, cerebrospinal fluid, or serum of affected individuals, antibody reactivity to viral antigens, and findings of elevated levels of CD46 (the receptor for HHV6). (dana.org)
  • Methods: Serum anti-col(V) antibodies were measured in asthma patients, and immunohistochemistry utilized to detect interstitial col(V) in fatal asthma. (iupui.edu)
  • tumor
  • FOR46 targets a novel immune modulatory receptor, CD46, which is highly expressed in multiple tumor types and is part of the tumor's immune defense shield. (businesswire.com)
  • While CD46 is expressed throughout the body, preclinical studies show that FOR46 activity is primarily restricted to prostate and other tumor tissue types, as opposed to normal tissue. (businesswire.com)
  • FOR46 cracks the code, in a sense, by binding a specific conformational epitope of CD46, that appears to be specific to tumor cells. (businesswire.com)
  • This results in targeted tumor killing, while not impacting the natural role of CD46 in the complement system. (businesswire.com)
  • By generating antibodies against tumor cells in situ, we developed a drug that readily translates to animal studies and, soon, human trials," said Marc Nasoff, Ph.D., Chief Scientific Officer of Fortis Therapeutics. (businesswire.com)
  • Of interest is that medulloblastoma (a malignant brain tumor common in childhood) specimens express a high level of CD46. (qedbio.com)
  • Dendritic cells (DCs) mount tumor-associated antigens (TAAs), and the double-stranded RNA adjuvant Poly(I:C) stimulates Toll-like receptor 3 (TLR3) signal in DC, which in turn induces type I interferon (IFN) and interleukin-12 (IL-12), then cross-primes cytotoxic T lymphocytes (CTLs). (biomedcentral.com)
  • Simultaneous administration of Poly(I:C) and antigen (Ag) OVA significantly increased a minor population of CD8 + T cells, that express CD11c in lymphoid and tumor sites. (biomedcentral.com)
  • Antibodies are well suited for eradicating tumor cells from the bloodstream and eliminating early tissue invasion ( 4 ). (aacrjournals.org)
  • Preclinical models have shown the clearance of circulating tumor cells and the elimination of systemic micrometastasis through the use of both passively administered and vaccine-induced antibodies ( 5 ). (aacrjournals.org)
  • CD55
  • Crry/CD46 and CD55, key to preventing complement activation, were down regulated on goblet cells in murine allergic airway disease. (iupui.edu)
  • Decreased expression of Crry/CD46 and CD55 on goblet cells may in part account for complement activation in asthma. (iupui.edu)
  • vaccine
  • To characterize the safety and immunogenicity of a heptavalent antigen-keyhole limpet hemocyanin (KLH) plus QS21 vaccine construct in patients with epithelial ovarian, fallopian tube, or peritoneal cancer in second or greater complete clinical remission. (aacrjournals.org)
  • donor
  • Protection against humoral injury mediated by donor-specific antibodies (DSA), also known as accommodation, may allow for long-term allograft survival in presensitized recipients. (nih.gov)
  • Accommodation in this model was associated with the prevention of the early antibody responses induced against donor antigens by complement inhibition. (nih.gov)
  • In contrast, in a discordant combination complement activation by preexisting antibodies in the recipient or by the vascular endothelium of the donor organ causes HAR of the xenograft . (springer.com)
  • Gene
  • CD8-LV mediated stable in vitro and in vivo reporter gene transfer as well as efficient transfer of genes encoding TCRs recognizing the melanoma antigen tyrosinase. (bloodjournal.org)
  • Whereas TCR gene-modified T cells recognize peptide-major histocompatibility complex (pMHC), CAR recognize antigen in an MHC-independent fashion. (bloodjournal.org)
  • CHO-Anti-Human CD46 MAb stable cell line is clonally-derived from a CHO cell line, which has been transfected with an Anti-human CD46 MAb gene to allow expression of the MAb. (creativebiomart.net)
  • Isotype
  • β-Gal activity normalised to total protein in (C) HSVSMC and (D) HSVEC infected with 5000 vp/cell in the presence or absence of CD46 function-blocking antibody MEM258 or an isotype matched control. (bio-rad-antibodies.com)
  • complement activation
  • Inhibition of complement activation with the Yunnan-cobra venom factor (Y-CVF) successfully prevented accelerated antibody-mediated rejection and resulted in successful accommodation and long-term renal allograft survival in most presensitized recipients. (nih.gov)
  • CD46 functions as an inhibitor of complement activation limiting the formation and activity of C3 convertases. (bio-rad-antibodies.com)
  • human
  • To create FOR46, the fully human antibody was conjugated to a potent payload using a proven chemistry platform with well-characterized in vivo properties. (businesswire.com)
  • A method is disclosed for preparing CDR-grafted humanized antibodies in which, in addition to the CDR's, non-human antibody residues are preferably used at positions 23, 24, 49, 71, 73 and 78 of the heavy chain variable region and at positions 46, 48, 58, and 71 of the light chain variable region. (google.ca)
  • CD46 also serves as a receptor for several human pathogens (both bacteria and viruses), and its ligation alteres T lymphocyte polarization toward antigen-presenting cells or target cells, inhibiting lymphocyte function. (sysmex-flowcytometry.com)
  • ELISA: use at 0.1-1ug/ml with human CD46 on the solid phase. (qedbio.com)
  • Figure B. APC conjugated Mouse anti Human CD3 ( MCA463APC ) and RPE conjugated Mouse anti Human CD46 ( MCA2113PE ). (bio-rad-antibodies.com)
  • Tested positive against native human antigen. (creativebiomart.net)
  • Further characterisation of CD46 , one of the genes upregulated in the DLL1 + cluster, revealed it to be a novel cell surface marker of human epidermal stem cells. (biologists.org)
  • reactivity
  • Longitudinal studies of reactivity to myelin antigens and to HHV6, and viral persistence/replication in relation to time-course of disease will be examined. (dana.org)
  • purification
  • Each antibody is crafted with care according to rigorous protocols for immunogen design and preparation, presentation to host animal, and high-affinity purification against the antigen. (abgent.com)
  • acquired immunity
  • Marie JC, Astier AL, Rivailler P, Rabourdin-Combe C, Wild TF, Horvat B: Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. (sysmex-flowcytometry.com)
  • epitopes
  • For established targets we seek to add antibodies that recognize new epitopes, including post-translational modifications such as phosphorylation and methylation. (abgent.com)
  • bacterial
  • A number of viral and bacterial pathogens seem to exploit this property and directly induce an immunosuppressive phenotype in T-cells by binding to CD46. (creativebiomart.net)
  • 2016
  • Fortis Therapeutics exclusively licensed rights to the antibody in 2016, and the company maintains a strong intellectual property position. (businesswire.com)
  • protein
  • The reference signal is usually generated either by staining an established marker protein with a differently fluorescently labeled antibody, by GFP-tagging, or by a fluorescent dye that accumulates at defined subcellular structures . (healthconnectionsvt.org)
  • However, the presence of anti-measles neutralizing antibodies (NAbs) against the hemagglutinin (H) protein of OMV is a major barrier to the therapeutic application of OMV in clinical practice. (springer.com)
  • viral
  • Corollary biologic studies included assessment of CRAd replication, wild type virus generation, viral shedding, and neutralizing antibody response. (pubmedcentralcanada.ca)
  • targets
  • For new targets we consult with leading experts to accelerate development of antibodies that will propel state-of-the-art research in cellular health and disease. (abgent.com)
  • ELISA
  • Periodic blood and urine samples were obtained to monitor safety (complete blood count, comprehensive panel, amylase, thyroid-stimulating hormone, and urinalysis) and antibody production (ELISA, fluorescence-activated cell sorting, and complement-dependent cytotoxicity). (aacrjournals.org)
  • cancers
  • CD46 is an attractive target for a number of cancers but has yet to be exploited due to its role in healthy tissues," said Jay Lichter, Ph.D., President and CEO of Fortis Therapeutics. (businesswire.com)